Journal
RESPIRATORY MEDICINE
Volume 106, Issue 3, Pages 329-337Publisher
W B SAUNDERS CO LTD
DOI: 10.1016/j.rmed.2011.12.006
Keywords
Adolescence; Asthma; Atopy; Bronchial hyper-responsiveness; Rhinitis; Paracetamol
Funding
- National Institutes of Health USA [5 R01 HL082925]
Ask authors/readers for more resources
Background: Understanding of adolescent-onset asthma remains limited. We sought to characterise this state and identify associated factors within a longitudinal birth cohort study. Methods: The Isle of Wight Whole Population Birth Cohort was recruited in 1989 (N = 1456) and characterised at 1, 2, 4, 10 and 18-years. Adolescent-onset asthma was defined as asthma at age 18 without prior history of asthma, persistent-adolescent asthma as asthma at both 10 and 18 and never-asthma as those without asthma at any assessment. Results: Adolescent-onset asthma accounted for 28.3% of asthma at 18-years and was of similar severity to persistent-adolescent asthma. Adolescent-onset asthmatics showed elevated bronchial hyper-responsiveness (BHR) and atopy at 10 and 18 years. BHR in this group at 10 was intermediate to that of never-asthmatics and persistent-adolescent asthma. By 18 their BHR, bronchodilator reversibility and sputum eosinophilia was greater than never-asthmatics and comparable to persistent-adolescent asthma. At 10, males who later developed adolescent-onset asthma had reduced FEV1 and FEF25-75, while females had normal lung function but then developed impaired FEV1 and FEF25-75 in parallel with adolescent asthma. Factors independently associated with adolescent-onset asthma included atopy at 10 (OR = 2.35; 95% CI = 1.08-5.09), BHR at 10 (3.42; 1.55-7.59), rhinitis at 10 (2.35; 1.11 5.01) and paracetamol use at 18-years (1.10; 1.01-1.19). Conclusions: Adolescent-onset asthma is associated with significant morbidity. Predisposing factors are atopy, rhinitis and BHR at age 10 while adolescent paracetamol use is also associated with this state. Awareness of potentially modifiable influences may offer avenues for mitigating this disease state. (C) 2011 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available